力生製藥(002393.SZ)轉讓天津新內田30%股權完成過户
格隆匯8月23日丨力生製藥(002393.SZ)公佈,公司將持有的天津新內田製藥有限公司(以下簡稱“天津新內田”)30%股權在天津產權交易中心公開掛牌轉讓,掛牌期間徵集到天津市青禾醫藥科技有限公司(以下簡稱“青禾醫藥”)一個意向受讓方,2019年7月19日,公司與青禾醫藥就天津新內田30%股權轉讓簽訂了《產權交易合同》,轉讓價款總額為人民幣1018.07萬元。
近日,公司收到交易對方青禾醫藥通過天津產權交易中心支付的購買天津新內田30%股權的轉讓價款總額為人民幣1018.07萬元。
截至本公告日,交易雙方已完成天津新內田30%股權過户的工商變更登記手續。公司不再持有天津新內田30%股權,預計將對公司經營業績和財務狀況有積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.